This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
McCully KS . Homocysteine and vascular disease. Nat Med 1996; 2: 386–389.
Mudd SH, Levy HL, Skovby F . Disorders of transulfuration. In: Scriver C, Beaudet AL, Sly WS, Valle D (eds). The Metabolic Basis of Inherited Disease. McGraw-Hill Book Co,: New York, 1989, pp 693–734.
Stabler SP et al. Elevation of total homocysteine in the serum of patients with cobalamin of folate deficiency detected by capillary gas chromatography–mass spectrometry. J Clin Invest 1998; 81: 466–474.
Frosst P et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995; 10: 111–113.
Perry IJ . Homocysteine, hypertension and stroke. J Hum Hypertens 1999; 13: 289–293.
Reports of the Second Task Force on Blood Pressure Control in Children. National Heart, Lung and Blood Institute, Bethesola, Maryland, 1987. Pediatrics 1987; 79: 1–25.
Boushey CJ, Beresford SA, Omenn GS, Motulsky AG . A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes [see comments]. JAMA 1995; 274: 1049–1057.
Brattstrom L, Wilcken DE, Ohrvik J, Brudin L . Common methylenetetrahydrofolate reductase gene mutation leads to hyperhomocysteinemia but not to vascular disease: the result of a meta-analysis. Circulation 1998; 98: 2520–2526.
Tsai JC et al. Promotion of vascular smooth muscle cell growth by homocysteine: a link to atherosclerosis. Proc Natl Acad Sci USA 1994; 91: 6369–6373.
El Kossi MM, Zakhary MM . Oxidative stress in the context of acute cerebrovascular stroke. Stroke 2000; 31: 1889–1892.
Kanani PM et al. Role of oxidant stress in endothelial dysfunction produced by experimental hyperhomocyst(e)inemia in humans. Circulation 1999; 100: 1161–1168.
Kitiyakara C, Gonin J, Massy Z, Wilcox CS . Non-traditional cardiovascular disease risk factors in end-stage renal disease: oxidate stress and hyperhomocysteinemia. Curr Opin Nephrol Hypertens 2000; 9: 477–487.
Mujumdar VS, Hayden MR, Tyagi SC . Homocyst(e)ine induces calcium second messenger in vascular smooth muscle cells. J Cell Physiol 2000; 183: 28–36.
Kosmala W . [Endothelial dysfunction in hypertension—clinical implications]. Pol Merkuriusz Lek 2002; 12: 333–335.
Groop L . Genetics of the metabolic syndrome. Br J Nutr 2000; 83: S39–S48.
Genest J . Plasma homocysteine levels in men with premature coronary artery disease. J Am Coll Cardiol 1990; 16: 1114–1119.
Sorensen TK et al. Elevated second-trimester serum homocyst(e)ine levels and subsequent risk of preeclampsia. Gynecol Obstet Invest 1999; 48: 98–103.
Yoo JH, Chung CS, Kang SS . Relation of plasma homocyst(e)ine to cerebral infarction and cerebral atherosclerosis. Stroke 1998; 29: 2478–2483.
Collaboration HLT . Lowering blood homocysteine with folic acid based supplements: meta-analysis of randomised trials. BMJ 1998; 316: 894–898.
Acknowledgements
This work was partially supported by Grants PID 0587 (Agencia Nacional de Promoción Científica y Técnica) and TM65 (Universidad de Buenos Aires) SIG, PIP and CJP belong to CONICET
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Garfunkel, V., Porto, P., Garcia, S. et al. Hyperhomocysteinemia but not MTHFR genotype is associated with young-onset essential hypertension. J Hum Hypertens 17, 361–364 (2003). https://doi.org/10.1038/sj.jhh.1001549
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.jhh.1001549